Azitra, Inc. Contract Liability (Deferred Revenue)
Azitra, Inc. (AZTR) had Contract Liability (Deferred Revenue) of $310.70 thousand as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-11-14
- 2023-06-30: Contract with Customer, Liability, Current $310.70K.
- 2022-12-31: Contract with Customer, Liability, Current $156.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-06-30 | $310.70K 10-Q · filed 2023-08-14 |
| 2022-12-31 | $156.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |